These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 31725610

  • 1. Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.
    Cai S, Zhong Z, Li X, Wang HX, Wang L, Zhang M.
    Medicine (Baltimore); 2019 Nov; 98(46):e17681. PubMed ID: 31725610
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
    Intern Med; 2007 Nov; 46(11):771-4. PubMed ID: 17541233
    [Abstract] [Full Text] [Related]

  • 5. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
    Furutera N, Fukunaga N, Okita J, Suzuki T, Suenaga Y, Oyama Y, Aoki K, Fukuda A, Nakata T, Uesugi N, Daa T, Hisano S, Shibata H.
    CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
    [Abstract] [Full Text] [Related]

  • 6. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
    Takeuchi N, Arai T, Kitaichi M, Inoue Y.
    BMJ Case Rep; 2013 Sep 26; 2013():. PubMed ID: 24072826
    [Abstract] [Full Text] [Related]

  • 7. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L.
    Hematol Oncol; 2018 Feb 26; 36(1):320-323. PubMed ID: 28401573
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
    Sugawara E, Sato T, Amasaki Y, Katsumata K.
    Medicine (Baltimore); 2022 Feb 25; 101(8):e28941. PubMed ID: 35212301
    [Abstract] [Full Text] [Related]

  • 11. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
    Galeotti C, Boucheron A, Guillaume S, Koné-Paut I.
    Mol Cancer Ther; 2012 Aug 25; 11(8):1623-6. PubMed ID: 22638145
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
    Lee JP, Kim DK, Oh DY, Paik JH, Moon KC, Kim S, Kim YS.
    Clin Nephrol; 2011 Feb 25; 75(2):165-70. PubMed ID: 21255547
    [Abstract] [Full Text] [Related]

  • 14. Cutaneous involvement as initial presentation of multicentric plasmacytic Castleman disease.
    Chen H, Ba W, Chen H, Yang H.
    J Cutan Pathol; 2021 May 25; 48(5):701-705. PubMed ID: 33469928
    [Abstract] [Full Text] [Related]

  • 15. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America.
    José FF, Kerbauy LN, Perini GF, Blumenschein DI, Pasqualin DDC, Malheiros DMAC, Campos Neto GC, de Souza Santos FP, Piovesan R, Hamerschlak N.
    Medicine (Baltimore); 2017 Mar 25; 96(13):e6271. PubMed ID: 28353560
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Castleman disease: retrospective single-center study of therapeutic results in 10 patients].
    Szturz P, Adam Z, Rehák Z, Koukalová R, Sprláková-Puková A, Michalka J, Smardová L, Volfová P, Lengerová M, Mayer J.
    Klin Onkol; 2013 Mar 25; 26(2):124-34. PubMed ID: 23718671
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.